Celebrating 25+ years of helping you give wisely
America's most independent,
assertive charity watchdog
Top Rated

Leukemia & Lymphoma Society

CharityWatch report issued
June 2018

Top-Rated Charity
A-
CharityWatch Grade
Our independent grade based
on a number of factors.
 
77%
Program Percentage
Amount spent on programs
relative to overhead.
 
$14
Cost to Raise $100
Amount spent to raise
$100 of contributions.

Contact Information

Leukemia & Lymphoma Society
3 International Drive
Rye Brook, NY 10573

Other Names

None

Tax Status

501(c)3

Website

www.lls.org

Stated Mission

To cure leukemia, lymphoma, Hodgkin's disease, and myeloma, and improve the quality of life of patients and their families.

View similar charities
Charity  
American Breast Cancer Foundation  
American Cancer Society  
American Institute for Cancer Research  
Avon Products Foundation  
Breast Cancer Charities of America  
Breast Cancer Outreach Foundation (DISSOLVED)  
Breast Cancer Prevention Partners  
Breast Cancer Research Foundation  
Breast Cancer Society (DISSOLVED)  
Cancer Care  
Cancer Fund of America (DISSOLVED)  
Cancer Recovery Foundation International  
Cancer Research Institute  
Cancer Survivors' Fund  
Childhood Leukemia Foundation  
Children's Cancer Fund of America (DISSOLVED)  
Children's Cancer Recovery Foundation  
Children's Cancer Research Fund  
CureSearch for Children's Cancer  
Damon Runyon Cancer Research Foundation  
Dana-Farber Cancer Institute  
Entertainment Industry Foundation  
Good Charity  
LiveStrong Foundation  
Memorial Sloan Kettering Cancer Center  
Multiple Myeloma Research Foundation  
National Breast Cancer Coalition Fund  
National Cancer Assistance Foundation  
National Cancer Center  
National Cancer Coalition (DISSOLVED)  
National Children's Cancer Society  
National Children's Leukemia Foundation (DISSOLVED)  
National Foundation for Cancer Research  
Ovarian Cancer Research Alliance  
Pancreatic Cancer Action Network  
Prevent Cancer Foundation  
Prostate Cancer Foundation  
St. Jude Children's Research Hospital  
Susan G. Komen Breast Cancer Foundation  
United Breast Cancer Foundation  
United Cancer Support Foundation  
Walker Cancer Research Institute  
Woman to Woman Breast Cancer Foundation (DISSOLVED)  
Data based on Fiscal Year Ended 06/30/2017

Program Percentage: 77%

The percentage of Leukemia & Lymphoma Society's cash budget it spends on programs relative to overhead (fundraising, management, and general expenses).

$317,000,000

Calculated Total Expenses

(rounded)

 

Cost to Raise $100: $14

How many dollars Leukemia & Lymphoma Society spends on fundraising to raise each $100 of contributions.

$315,000,000

Calculated Total Contributions

(rounded)

Joint Costs

Leukemia & Lymphoma Society's rating was adjusted for Joint Costs. If you are a donor who considers direct mail, telemarketing, and other Joint Cost solicitations to be true charitable programs, the below efficiency ratios, which were not adjusted for joint costs, may better reflect your goals.

Program % Cost to Raise $100
79% $12
Accounting rules allow charities to report some telemarketing, direct mail, and other solicitation costs as Program expenses. CharityWatch believes that most donors do not consider a charity's solicitation activities to be the Programs they are intending to support with their donations. We therefore adjust such expenses out of a charity's reported Program expense and add it to Fundraising expense prior to calculating its rating.

Government Funding

0% to 24%

Percentage of cash revenue
coming from government sources

 

Financial Documents

Entity Document Type Tax ID
The Leukemia & Lymphoma Society IRS Form 990 13-5644916
The Leukemia & Lymphoma Society Consolidated Audited Financial Statements Multiple
Entity: The Leukemia & Lymphoma Society
Document Type: IRS Form 990
Tax ID: 13-5644916
Entity: The Leukemia & Lymphoma Society
Document Type: Consolidated Audited Financial Statements
Tax ID: Multiple

Governance & Transparency

CharityWatch evaluates certain criteria related to a charity's Governance and Transparency. Donors may want to consider a charity's willingness to be open and transparent with CharityWatch to be a good litmus test for determining its commitment to public accountability.
This charity is Top-Rated
What does it mean to be Top-Rated?
 
Leukemia & Lymphoma Society
meets governance benchmarks.
 
Leukemia & Lymphoma Society
meets transparency benchmarks.
Transparency
Provides Financial Information
Audit Accessibility
Governance: Policies
Reports regularly & consistently monitoring & enforcing compliance with a written Conflict of Interest Policy
Reports required, annual disclosure by officers, directors, and key staff of interests that could give rise to conflicts
Reports having a written Whistleblower Policy
Reports having a written Document Retention and Destruction Policy
Governance: Financials
Reports providing copy of tax form to all board members prior to filing it with IRS
Reports that financial statements were audited by an independent accountant
Governance: Board of Directors
Reports at least 5 voting board members
51% or more of voting board members reported as independent
Reports documenting minutes of board and board committee meetings
Privacy Policy
Privacy Policy Opt-Out Policy  

  Name Title Compensation
1 Louis J. Degennaro President/CEO $623,559
2 Mark Roithmayr Past Executive VP/Chief Relationship Officer $451,090
3 Rosemarie A. Loffredo Executive VP/CFO $415,910
1
Name: Louis J. Degennaro
Title: President/CEO
Compensation: $623,559
2
Name: Mark Roithmayr
Title: Past Executive VP/Chief Relationship Officer
Compensation: $451,090
3
Name: Rosemarie A. Loffredo
Title: Executive VP/CFO
Compensation: $415,910

CharityWatch Analysts perform an in-depth analysis of charities' audited financial statements and IRS tax filings, and often review other documents such as state filings, annual reports, and fundraising contracts during their evaluations. Below are select notes that CharityWatch believes may be of interest to donors.
CharityWatch's rating of Leukemia & Lymphoma Society (LLS) is based The Leukemia & Lymphoma Society audited consolidated financial statements for the fiscal year-ended 6/30/2017.

According to The Leukemia & Lymphoma Society fiscal 2017 consolidated audit (Note 1(B), Principles of Consolidation):

"The accompanying [audited] consolidated financial statements include the accounts of LLS that encompass the National Office of LLS and its fifty-six chapters in the United States, and LLS's not-for-profit affiliates, including The Leukemia & Lymphoma Society of Canada, Inc. (LLSC) and its five chapters in Canada, The Leukemia & Lymphoma Society Research Programs, Inc. (LLSRP), The Leukemia & Lymphoma Society Research Foundation (LLSRF), Beat AML LLC (BAML) and PearlPoint Cancer Support, Inc. (PPCS). ... All significant inter-company and intra-LLS accounts and transactions have been eliminated in consolidation."
According to The Leukemia & Lymphoma Society (LLS) consolidated audit of June 30, 2017 (Note 7, Donated Goods, Services and Media), LLS received "donated goods, donated services for family support group facilitators and research grant reviewers, as well as donated media" on which it placed a total value of approximately $14.6 million in fiscal 2017. The value of the donated media constituted approximately $8.6 million of the total.

[Note: CharityWatch generally excludes the value of in-kind (non-cash) donations of goods and services from its calculations of Program % and Cost to Raise $100. More information on how grades are calculated and the treatment of in-kind donations can be found on the Our Process page.]
According to The Leukemia & Lymphoma Society (LLS) consolidated audit of June 30, 2017 (Note 8, Fixed Assets, Net) [$s in thousands, as noted]:

"In 2017, an impairment of fixed assets of $5,434 [thousand] was recorded for the write-off [of] a fund-raising platform that will no longer be utilized by LLS."
According to The Leukemia & Lymphoma Society (LLS) tax filing for the fiscal year ended June 30, 2017 re: Compensation Information, LLS reports paying severance in the amounts of $220,328, $125,350, and $111,126 to Paulette Damiano, Michele Przypyszny, and George J. Omiros, respectively, in the calendar year 2016 (IRS Form 990, Schedule J, Part III).

Paulette Damiano is reported as "VP Org Dev & Change," term 6/30/2016, with total compensation of $339,547. Michele Przypyszny is reported as "Executive Director," term 7/21/2016, with total compensation of $258,685. George J. Omiros is reported as "EVP-Chief Camp&Field," term April 2015, with total compensation of $111,126. The reported total compensation amounts include the respective severance payments noted above and are for the calendar year 2016 (IRS Form 990, Schedule J, Part II).


LLS also reports re: Compensation Information:

"Bonuses were paid based on the achievement of the employee individual performance. Bonuses were capped according to LLS's policy..." (IRS Form 990, Schedule J, Part III).

For Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees compensated more than $100,000 in 2016, LLS reports paying seven individuals "Bonus & incentive compensation." Four individuals were paid "Bonus & incentive compensation" in amounts that ranged from $11,068 to $19,082. In addition, "Bonus & incentive compensation" in the amount of $51,000, $36,593, and $32,500 was paid to Rosemarie A. Loffredo (EVP - CFO), Mark Roithmayer (EVP Chief Rel Office, term 12/31/2016), and Andrew S. Coccari (EVP Chief Prod Office), respectively. The reported total compensation in 2016 for R. Loffredo, M. Roithmayer, and A. Coccari was $415,910, $451,090, and $383,874, respectively, including the bonus payments (IRS Form 990, Schedule J, Part II).

Related Articles

No related articles found